Critical Evaluation of the Efficacy and Safety of Anticholinergics in Overactive Bladder  Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements  Volume 6, Issue 5, Pages 425-431 (March 2007) DOI: 10.1016/j.eursup.2006.12.015 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Receptor profiles of available antimuscarinic agents. European Urology Supplements 2007 6, 425-431DOI: (10.1016/j.eursup.2006.12.015) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Change in daily micturition frequency in patients with overactive bladder treated with solifenacin 5 or 10mg once daily or 4mg once-daily extended-release tolterodine; the STAR Study [7]. European Urology Supplements 2007 6, 425-431DOI: (10.1016/j.eursup.2006.12.015) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Change in daily episodes of urgency, urge incontinence, and incontinence in patients with overactive bladder treated with solifenacin 5 or 10mg once-daily or 4mg once-daily extended-release tolterodine; the STAR Study. *p<0.05; **p<0.01. Reprinted from Chapple CR, et al. Eur Urol 2005;48:464–70, © 2005, with permission from the European Association of Urology. European Urology Supplements 2007 6, 425-431DOI: (10.1016/j.eursup.2006.12.015) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Effect of anticholinergics compared with placebo on patient perception of cure or improvement in symptoms of overactive bladder. Reproduced with permission from BMJ Publishing Group Ltd. Herbison P, et al. BMJ 2003;326:841–4. European Urology Supplements 2007 6, 425-431DOI: (10.1016/j.eursup.2006.12.015) Copyright © 2007 European Association of Urology Terms and Conditions